{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Amicus Therapeutics, Inc.
Amicus Therapeutics Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators
Amicus Therapeutics, Inc. has recently undergone an evaluation revision amid mixed technical performance indicators. The stock, priced at $14.46, has shown significant annual returns of 109.57%, outperforming the S&P 500. Its resilience and competitive positioning are underscored by this recent assessment in the pharmaceuticals and biotechnology sector.
Amicus Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance
Amicus Therapeutics, Inc. has shown impressive performance over the past year, achieving a 122.12% return, significantly outperforming the S&P 500. The stock has maintained stability within a defined price range, reflecting resilience and adaptability in the competitive biotechnology sector, despite mixed technical indicators.
Amicus Therapeutics Hits New 52-Week High of $14.48
Amicus Therapeutics, Inc. has achieved a new 52-week high, reflecting a strong performance with a significant increase over the past year. The company, with a market capitalization of USD 4,512 million, maintains a manageable debt level but is currently operating at a loss, emphasizing its ongoing strategic focus in biotechnology.
Amicus Therapeutics Hits New 52-Week High of $14.47
Amicus Therapeutics, Inc. has achieved a new 52-week high of USD 14.47, reflecting a significant increase from its previous low of USD 5.51. The company, with a market capitalization of USD 4,512 million, operates in the Pharmaceuticals & Biotechnology sector and has a manageable debt-to-equity ratio of 0.59.
Amicus Therapeutics Hits New 52-Week High of $14.43
Amicus Therapeutics, Inc. achieved a new 52-week high of USD 14.43 on March 20, 2026, reflecting a significant increase from its previous low of USD 5.51. The company, with a market capitalization of USD 4,512 million, continues to navigate its financial landscape despite being loss-making.
Amicus Therapeutics Experiences Revision in Stock Evaluation Amid Strong Market Performance
Amicus Therapeutics, Inc. has recently revised its evaluation amid current market dynamics. The stock, priced at $14.33, has shown mixed technical indicators. Over the past year, it has significantly outperformed the S&P 500, indicating a strong recovery and solid market position.
Amicus Therapeutics Experiences Revision in Stock Score Amid Mixed Financial Performance
Amicus Therapeutics, Inc. reported strong operating cash flow of USD 33.14 million for the quarter ending December 2025, with a half-year net profit of USD 19 million. However, pre-tax profit and net profit for the quarter saw significant declines, while the company demonstrated resilience with a notable stock return over the past year.
Amicus Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout
Amicus Therapeutics, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. Current technical indicators present a mixed outlook, with short-term bullish signals contrasted by bearish longer-term indicators. The stock has faced challenges over the past year but has shown recent resilience, outperforming the S&P 500.
Is Amicus Therapeutics, Inc. technically bullish or bearish?
As of October 10, 2025, Amicus Therapeutics, Inc. shows a mildly bullish trend with mixed signals from technical indicators, having returned 1.22% over the past week and 4.53% over the past month, but is down 11.89% year-to-date compared to the S&P 500's 11.41% gain.
Is Amicus Therapeutics, Inc. technically bullish or bearish?
As of October 10, 2025, Amicus Therapeutics, Inc. shows a mildly bullish trend with a 4.53% monthly return, but has underperformed year-to-date at -11.89% compared to the S&P 500's 11.41%, amid mixed technical signals.
Is Amicus Therapeutics, Inc. technically bullish or bearish?
As of August 1, 2025, Amicus Therapeutics, Inc. has a mildly bearish trend, with mixed technical indicators and underperformance against the S&P 500, showing a year-to-date return of -9.98% compared to the index's 12.22%.
Is Amicus Therapeutics, Inc. overvalued or undervalued?
As of November 7, 2016, Amicus Therapeutics, Inc. is considered risky and overvalued compared to its peers, with a high Price to Book Value of 9.80 and an EV to EBITDA ratio of 36.52, while its stock has underperformed over the year with a return of -9.98% compared to the S&P 500's 12.22%.
Is Amicus Therapeutics, Inc. overvalued or undervalued?
As of November 7, 2016, Amicus Therapeutics, Inc. is considered risky and overvalued due to high Price to Book and EV to EBITDA ratios, a negative ROE, and significant underperformance compared to the S&P 500.
Is Amicus Therapeutics, Inc. technically bullish or bearish?
As of February 19, 2025, Amicus Therapeutics, Inc. has a bearish technical outlook, indicated by negative MACD, moving averages, and KST across multiple time frames, along with underperformance compared to the S&P 500.
Who are in the management team of Amicus Therapeutics, Inc.?
As of March 2022, the management team of Amicus Therapeutics, Inc. includes Chairman and CEO John Crowley, President and COO Bradley Campbell, and several independent directors: Michael Raab, Lynn Bleil, Robert Essner, Michael Kelly, and Margaret McGlynn.
What does Amicus Therapeutics, Inc. do?
Amicus Therapeutics, Inc. is a biotechnology company focused on developing treatments for rare metabolic diseases, with a market capitalization of approximately $1.79 billion. As of March 2025, it reported net sales of $125 million and a net loss of $22 million.
How big is Amicus Therapeutics, Inc.?
As of Jun 18, Amicus Therapeutics, Inc. has a market capitalization of $1.786 billion, with net sales of $543.15 million and a net profit of -$29.38 million over the latest four quarters. The company reported shareholder's funds of $194.04 million and total assets of $785.03 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
